PAXIPAM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PAXIPAM (PAXIPAM).
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
| Metabolism | Hepatic via CYP450 (primarily CYP2C19 and CYP3A4) to active metabolites (N-desalkylflurazepam). |
| Excretion | Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%. |
| Half-life | Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment. |
| Protein binding | 92-98% bound to albumin. |
| Volume of Distribution | 0.5-1.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 80-100%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 1-5 minutes. |
| Duration of Action | Oral: 6-8 hours; intravenous: 2-4 hours; clinical notes: Duration may be extended with repeated dosing due to accumulation. |
| Molecular Weight | 342.86 |
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: no adjustment; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated. |
| Pediatric use | Children 6-12 years: 0.5-1 mg/kg/day divided every 6-8 hours, not to exceed 20 mg/day; Children <6 years: not recommended. |
| Geriatric use | Initiate at 2.5 mg every 12 hours; titrate cautiously due to increased sensitivity and risk of falls. |
| 1st trimester | Teratogenic risk: limited human data; animal studies show increased risk of cleft palate and skeletal anomalies at high doses. Use only if benefit outweighs risk. |
| 2nd trimester | Risk of fetal growth restriction and neurodevelopmental effects; avoid if possible. |
| 3rd trimester | Risk of neonatal withdrawal and floppy infant syndrome; avoid during third trimester. |
Clinical note
Comprehensive clinical and safety monograph for PAXIPAM (PAXIPAM).
| Placental transfer | A: Paxipam crosses the placenta; equilibrium is reached between maternal and fetal plasma concentrations. |
| Breastfeeding | Paxipam is excreted into breast milk in low concentrations; however, long-term effects on the nursing infant are unknown. Monitor infant for drowsiness and poor feeding. Use with caution. |
■ FDA Black Box Warning
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients without adequate alternative treatment options.
| Serious Effects |
Hypersensitivity to alprazolam or other benzodiazepinesSevere hepatic impairmentNarrow-angle glaucomaConcurrent use with itraconazole, ketoconazole, or other CYP3A4 inhibitors causing significant accumulation
| Precautions | Risk of dependence and withdrawal; CNS depressant effects; impaired psychomotor function; anterograde amnesia; worsening of depression; respiratory depression in COPD/sleep apnea; elderly fall risk. |
| Food/Dietary | Grapefruit and grapefruit juice may increase the effects of PAXIPAM and should be avoided. Avoid alcohol and any products containing alcohol (e.g., certain mouthwashes) as they can potentiate CNS depression. |
Loading safety data…
| Lactation Rating |
| L3 - Moderately Safe |
| Teratogenic Risk | Paxipam (halazepam) is a benzodiazepine. First trimester: Increased risk of congenital malformations including oral cleft. Second trimester: Risk persists but lower; possible adverse neurodevelopmental effects. Third trimester: Risk of neonatal withdrawal, floppy infant syndrome, and respiratory depression. |
| Fetal Monitoring | Monitor maternal vital signs and sedation level. Fetal monitoring: ultrasound for congenital anomalies if exposed in first trimester; neonatal monitoring for respiratory depression, hypotonia, and withdrawal symptoms after delivery. |
| Fertility Effects | No specific data on halazepam; benzodiazepines may cause menstrual irregularities and reduced libido; impact on fertility not established. |
| Clinical Pearls | PAXIPAM is a benzodiazepine used primarily for alcohol withdrawal and anxiety. Monitor for respiratory depression, especially in patients with COPD or sleep apnea. Use lowest effective dose for shortest duration due to dependence potential. Avoid in myasthenia gravis and severe hepatic impairment. Flumazenil is reversal agent but use cautiously in chronic benzodiazepine users due to seizure risk. |
| Patient Advice | Do not drive or operate heavy machinery until you know how this medication affects you. · Avoid alcoholic beverages completely while taking PAXIPAM. · Do not stop taking this medication abruptly; withdrawal symptoms can be severe. · Inform your doctor if you have a history of substance abuse, depression, or breathing problems. · This medication can be habit-forming; use only as prescribed. |